Neuroepo multisession
Resting-state EEG recorded from 25 patients with Parkinson's disease in a double-blind, randomized, placebo-controlled trial of Neuroepo, an EPO formulation with low sialic acid content. Recordings were acquired before and six months after drug administration, in Neuroepo (n=15) and placebo (n=10) groups. The raw data are shared in EEG-BIDS format to support evaluation of EEG biomarkers of neuroprotection, including qualitative expert ratings and quantitative source-level analysis.
- Participants
- 15
- Size
- 189 MB
- Version
- vv1.0.0
- Updated
- Nov 10, 2026